The market for biosimilars will increase as more biologic drugs reach patent expiry within the next 10 years. It is an area which pharma companies such as Merck are vying for a share of the market as are the major generic manufacturers. A clear regulatory pathway in the US is required and companies are positioning themselves in preparedness for such a pathway.